ArticleFrontiers in oncology2026
Prognostic significance of ZNF695 in uterine corpus endometrial carcinoma: single-cell and immune infiltration analyses.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zinc Finger Protein 695 (ZNF695) has been reported as a prognostic indicator in several cancers; however, its clinical implications and functional contributions within uterine corpus endometrial carcinoma (UCEC) have not yet been elucidated. Herein, the prognostic significance of ZNF695 in UCEC and its potential involvement in immune infiltration were examined. Methods: Bioinformatics analyses were conducted utilizing The Cancer Genome Atlas (TCGA) data to evaluate ZNF695 expression, its impact on survival, and patient clinicopathological features. ZNF695 protein expression and subcellular localization were validated using immunohistochemistry (IHC) on a UCEC tissue microarray. To dissect tumor heterogeneity and immune microenvironment, single-cell RNA-seq data from the Gene Expression Omnibus (GEO) were analyzed. The immune infiltration patterns were evaluated utilizing the CIBERSORT algorithm. Three prognostic nomograms were developed to assess UCEC patient survival at the 1-, 3-, and 5-year marks. Furthermore, Results: ZNF695 was significantly elevated in UCEC and associated with various clinicopathological features including age, body weight, menopause status, clinical stage, and histological grade. Functional enrichment analyses indicated that ZNF695 was involved in key biological functions, including endopeptidase regulator activity, estrogen signaling pathway and MYC targets. Additionally, single-cell subgroup analysis isolated different cell populations with high ZNF695 expression, underscoring its role in tumor microenvironment. Immune infiltration analyses indicated negative correlations between ZNF695 and various immunosuppressive immune cell subtypes. Elevated ZNF695 expression was strongly correlated with unfavorable clinical outcomes in UCEC. The nomograms for overall survival (OS), disease specific survival (DSS), and progression free interval (PFI) demonstrated promising predictive efficacy, with concordance indices (C-indexes) of 0.631, 0.719, and 0.787, respectively. Conclusion: ZNF695 serves as an independent prognostic biomarker for UCEC, with its potential as a molecular marker validated experimentally. These findings emphasize the critical role of ZNF695 in regulating the immune landscape of UCEC, warranting studies to elucidate underlying molecular mechanisms and explore its clinical translational implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.